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cannabis, and reporting solitary use up to age 16. However, with regards to 
current use, controls were currently using more heavily across these param-
eters than patients.
Discussion: Patients who develop psychosis decrease substance consump-
tion after adolescence compared to other non-psychotic substance users. 
A  history of heavy early use of cannabis may be a tractable target for 
intervention.
F103. A META-ANALYSIS OF PERSONALITY 
TRAITS IN DUAL DIAGNOSIS PSYCHOSIS AND 
SUBSTANCE USE DISORDER
Hyeonju Oh*,1, Seon-Kyeong Jang2, Kee-Hong Choi1
1Korea University; 2University of Minnesota, Twin Cities
Background: The comorbidity of substance use and psychotic disorders has 
been constantly explored in psychosis literature due to its markedly high 
prevalence and its contribution in debilitating outcomes in various aspects 
(e.g., lower therapeutic compliance, higher rate of relapse, longer hospitali-
zation, homelessness, and poorer overall functioning). One promising con-
ceptualization of substance use disorder in schizophrenia is understanding 
shared personality traits such as impulsivity. Thus far, empirical evidences 
indicated several personality traits as candidate such as impulsivity, neu-
roticism and anhedonia. However, the accumulated empirical data remains 
inconsistent across studies. Current study aimed to aggregate data regard-
ing trait personality features in facet level utilizing four-factor UPPS model 
(Whiteside & Lynam, 2001), four-factor Hierarchical Structural Model 
(Markon, Krueger, & Watson, 2005), and anhedonia scale for investigating 
personality traits of impulsivity, neuroticism and anhedonia.
Methods: A systematic literature research was conducted using PubMed, 
Google Scholar, Scopus, and ProQuest, dissertation database in Proquest, 
and hand searches from reference lists of identified articles. Our analy-
sis covers all studies published up to May 2017. The electronic database 
research resulted in an initial pool of 110 studies in total, and 12 stud-
ies remains for current meta-analysis after screening by inclusion/exclu-
sion criteria and removing duplicate studies. Two authors (SKJ and HJO) 
independently coded data, and all authors cross-checked to ensure the reli-
ability of coded data to reach consensus. Effect-size estimates were calcu-
lated based on means and standard deviations of psychotic disorder only 
group (PSD) and dual diagnosis group (DD) on personality scales using R 
package metafor. Specifically, Hedges’ g was derived with a random-effect 
model, allowing unbiased effect sizes adjusted for different sample sizes that 
helps to infer population-level estimates. To examine potential confounding 
factors, independent two-sample t-tests were conducted between DD and 
PSD group for any significant differences in demographic and clinical char-
acteristics. Fail-Safe N test was utilized to address publication bias of the 
current meta-analysis, and inconsistency of data was assessed using heter-
ogeneity measure (I2). The methodological quality assessment of included 
studies was created by using an adapted version of Agency for Healthcare 
Research and Quality (AHRQ) tool for observational studies.
Results: There were no statistically significant baseline differences in dem-
ographic and clinical characteristics between DD and PSD group. The 
results indicate that DD patients exhibited significantly higher scores on 
negative urgency, low premeditation, and sensation seeking compared to 
PSD within the UPPS model. However, low perseveration did not differ 
between two groups. Within the HS model, unconscientious disinhibition 
was significantly higher in DD compared to PSD, but not negative affect, 
disagreeable disinhibition, and positive affect. Lastly, trait anhedonia score 
was not significantly different between groups.
Discussion: Despite a limited number of available studies, our meta-analy-
sis allowed to specify the personality trait in facet level of dual diagnosis 
patients compared to patients without substance use disorder. We con-
clude that the personality trait of DD patients may lead to the employment 
of urgent emotional regulation strategies (i.e. substance use) to alleviate 
negative emotion. More effective emotion regulations strategies (e.g., mind-
fulness, emotion tolerance skills, etc) might need to be integrated for treat-
ment for DD patients.
F104. A STANDARDISED EMPIRICAL 
INVESTIGATION OF THE CLINICAL PROFILE OF 
PSYCHOSIS FOLLOWING TRAUMATIC BRAIN 
INJURY (PFTBI)
Rachel Batty*,1, Neil Thomas1, Andrew Francis2, 
Malcolm Hopwood3, Jennie Ponsford4, Susan Rossell2
1Swinburne University of Technology; 2RMIT University; 
3University of Melbourne; 4Monash-Epworth Rehabilitation 
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Background: Persons who experience symptoms of psychosis following a 
brain injury live with a complex dual diagnosis that is often accompanied 
by substantial distress and disability. However, a comprehensive examina-
tion of the clinical presentation of PFTBI using standardised clinical meas-
ures has not been reported in the literature. This information is vital for 
accurate diagnosis and effective treatment.
Methods: Patients with PFTBI (n =10) and schizophrenia (n =98) participated 
in a comprehensive clinical assessment that included the Structured Clinical 
Interview for DSM-IV-TR Axis I  Disorders (SCID-I/P), the Positive and 
Negative Syndrome Scale (PANSS), the Scale for the Assessment of Positive 
Symptoms (SAPS), the Scale for the Assessment of Negative Symptoms 
(SANS), and the Thought Language and Communication Index (TLC).
Results: The clinical profiles of the PFTBI group met symptom/course criteria 
for: schizophrenia (n = 6), schizoaffective (n = 2), schizophreniform (n = 1), 
and paranoid psychosis (n = 1). PFTBI patients had a significantly reduced 
PANSS negative score relative to schizophrenia patients. No other significant 
differences between PFTBI and schizophrenia clinical profiles were found.
Discussion: The clinical profile of PFTBI appears to be comparable to 
schizophrenia/ schizoaffective disorder except with respect to negative psy-
chotic symptoms. Reduced negative symptoms in PFTBI have previously 
been reported in a small number of case studies, and thus warrant further 
investigation as a diagnostic distinction in this patient group.
F105. MEASURING EMPATHY IN 
SCHIZOPHRENIA: THE EMPATHIC ACCURACY 
TASK AND ITS CORRELATION WITH OTHER 
EMPATHY MEASURES
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Marije aan het Rot3, Alexander Wunderink4, Paul Lysaker5,  
Ilanit Hasson-Ohayon6, Andre Aleman7,  
Marieke (Gerdina) Pijnenborg3
1GGZ Friesland, Rijksuniversiteit Groningen; 2Department of 
Psychotic Disorders Assen,3Rijksuniversiteit Groningen; 4Friesland 
Mental Health Services; 5Roudebush VA Medical Center, Indiana 
University School of Medicine; 6Bar-Ilan University; 7University 
Medical Center Groningen
Background: Empathy is a complex interpersonal process thought to 
be impaired in individuals with schizophrenia spectrum disorders. Past 
studies have mainly used questionnaires or performance-based tasks 
with static cues to measure cognitive and affective empathy. In contrast, 
we used an Empathic Accuracy Task (EAT) designed to capture the 
more dynamic aspects of  empathy by using video clips in which perceiv-
ers continuously judge emotionally charged stories of  various targets. 
We compared individuals with schizophrenia to healthy controls on the 
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EAT and assessed correlations among the EAT and three other com-
monly used empathy tasks.
Methods: Patients (n=92) and healthy controls (n=42) matched for 
age and education, completed the EAT, the Interpersonal Reactivity 
Index, the Questionnaire of  Cognitive and Affective Empathy and the 
Faux Pas task. Differences between groups were analyzed and correla-
tions were calculated between empathy measurement instruments.
Results: The groups differed in EAT performance, with controls outper-
forming patients. A moderating effect was found for the emotional expres-
sivity of  the target: while both patients and controls scored low when 
judging targets with low expressivity, controls performed better than 
patients with more expressive targets. Though there were also group dif-
ferences on the cognitive and affective empathy questionnaires (with lower 
scores for patients in comparison to controls), EAT performance did not 
correlate with questionnaire scores. Reduced empathy performance did not 
seem to be part of  a generalized cognitive deficit, as differences between 
patients and controls on general cognition was not significant.
Discussion: Individuals with schizophrenia benefit less from the emotional 
expressivity of other people than controls, which contributes to their impaired 
empathic accuracy. The lack of correlation between the EAT and the question-
naires suggests a distinction between self-report empathy and actual empathy 
performance. To explore empathic difficulties in real life, it is important to use 
instruments that take the interpersonal perspective into account.
F106. STATE AND TRAIT RELATED NATURE OF 
INSIGHT IMPAIRMENT IN SCHIZOPHRENIA
Lebogang Phahladira*,1, Bonginkosi Chiliza2, Laila Asmal1, 
Sanja Kilian1, Freda Scheffler1, Robin Emsley1
1Stellenbosch University; 2University of KwaZulu Natal
Background: Impairment of insight is a prominent feature of schizophrenia and 
is associated with poor adherence and poor outcomes. While many studies have 
investigated the nature of insight impairment in schizophrenia, few have charted 
its course longitudinally. In this study we investigated changes in different com-
ponents of insight during the first 12 months of antipsychotic treatment.
Methods: The sample comprised 107 never or minimally treated patients with 
a first episode of schizophrenia, schizophreiform or schizoaffective disorder. 
They were treated according to a fixed protocol with flupenthixol decano-
ate. Insight was assessed with the self-rating Birchwood Insight Scale and the 
investigator rated global insight item of the PANSS scale.Psychopathology was 
assessed with the PANSS and CDSS. Cognitive performance was assessed with 
the MATRICS. We performed evaluations at baseline, month 6 and month 12. 
Linear mixed effects mixed models for repeated measures were conducted to 
assess changes over time, adjusting for age, gender and educational status.
Results: There were no significant changes in the BIS subscales of  symp-
tom awareness, awareness of  illness or total BIS score. The need for 
treatment subscale improved slightly (p=0.02) while the PANSS global 
insight improved considerably (p<0.0001). Degree of  insight impair-
ment was only weakly correlated with psychopathology and cognition
Discussion: Insight impairment is common in schizophrenia and displays 
trait-like rather than state-like features. These findings have important clini-
cal implications.
F107. CSF ABNORMALITIES IN SCHIZOPHRENIA 
AND DEPRESSION: PRELIMINARY RESULTS 
FROM A LARGE SCALE COHORT
Tatiana Oviedo Salcedo*,1, Anna Gagsteiger1, Lot de Witte2, 
Tania Kümpfel1, René Kahn2, Peter Falkai1, Peter Eichhorn1, 
Jurjen Luykx2, Alkomiet Hasan1
1Ludwig Maximilian University; 2University Medical Center 
Utrecht, Brain Center Rudolf Magnus
Background: CSF abnormalities and a neuroinflammatory pathophysi-
ology have been discussed for affective and non-affective psychosis for 
more than 30-years. Recent studies pointed towards a specific pheno-
type of  autoimmune-antibody mediated psychosis, but evidence is still 
sparse. Especially CSF data investigating autoimmune antibodies in 
large-scale CSF cohorts of  affective and non-affective psychoses are 
lacking.
Methods: We analyzed a retrospective naturalistic cohort of 592 patients 
with A) schizophrenia-spectrum disorders (N = 330) or B) depressive dis-
orders (N = 262) who underwent a lumbar puncture as part of the clinical 
routine in the Department of Psychiatry and Psychotherapy at the Ludwig-
Maximilians University Munich between July 2012 and May 2017. We used 
a predefined systematic algorithm for the database search in the clinical 
documentation system and data was extracted by TO and AG. The study 
was approved by the local ethics committee.
Results: We identified 592 patients with standard CSF parameters. 
Schizophrenia spectrum patients did not differ from depressive patients 
with regard to the white blood cell count (cells/µl) (p  =  0.774) or albu-
min quotient (p  =  0.663). The general prevalence of oligoclonal bands 
did not differ between groups (schizophrenia: 37.0%, depression: 37.8%; 
p  =  0.838). However, schizophrenia patients showed higher frequencies 
for intrathecal oligoclonal bands (32% of all oligoclonal bands) com-
pared to depressive patients (19.1% of all oligoclonal bands. (p = 0.034). 
124 schizophrenia-spectrum patients (54 first-episode patients) received 
CSF analyses for neural antibodies. None of the patients showed pos-
itive CSF results in any of the tested autoimmune-encephalitis panel 
(NMDA(N=119), AMPA-1(N=114), AMPA-2(N=114), CASPR(N=111), 
LGI-1(N=110) and GABA-B(N=112)-Antibodies) in CSF. The results for 
the intracellular onconeuronal and synaptic antibodies were also negative 
(Amphyphysin(N=93), Yo(N=58), Hu(N=94), Ri(N=94), CV2(N=93), 
Ma1(N=93) and Ma2(N=93)-Antibodies). Three of these patients with 
negative CSF titers did have low-titer neuronal antibodies in serum: 
CASPR-2-AB: 1:10, CASPR-2-AB: 1:50, Yo-AB: low band-intensity. 36 
depression patients were also tested for autoimmune antibodies and again 
no positive reports could be identified in CSF.
Discussion: This is the first analyses of autoimmune antibodies in first-
episode and recurrent schizophrenia and depressive mood disorder show-
ing no positive CSF titers. However, schizophrenia patients have a higher 
prevalence of intrathecal oligoclonal bands compared to affective patients 
pointing towards more immunological disturbances in this population. The 
here presented analyses are exploratory and need to undergo confirmatory 
analyses and quality control.
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A NORWEGIAN SAMPLE - TENTATIVE RESULTS 
OF A QUESTIONNAIRE VALIDATION
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Background: Auditory verbal hallucinations are a major symptom in 
schizophrenia but also affect patients with other diagnoses and healthy peo-
ple without any pathology. This applies also to delusions and hallucinations 
of other sensory modalities. Since most questionnaires that assess halluci-
nations focus on one particular disorder, the Questionnaire for Psychotic 
Experiences (QPE) was created to provide an instrument that is applicable 
independently of clinical status.
